Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy
Allergy · 2024-04 · 79 (4) · 894-907
DOI: 10.1111/all.16001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, online erschienen am 27.01.2024. Verfasst von Matthew F Wipperman und 17 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA. Hauptthemen laut MEDLINE: Transcriptome, Rhinitis, Allergic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Regeneron Pharmaceuticals, Sanofi.
Abstract (Originalsprache)
Background
Nasal epithelial cells are important regulators of barrier function and immune signaling; however, in allergic rhinitis (AR) these functions can be disrupted by inflammatory mediators. We aimed to better discern AR disease mechanisms using transcriptome data from nasal brushing samples from individuals with and without AR.
Methods
Data were drawn from a feasibility study of individuals with and without AR to Timothy grass and from a clinical trial evaluating 16 weeks of treatment with the following: dupilumab, a monoclonal antibody that binds interleukin (IL)‐4Rα and inhibits type 2 inflammation by blocking signaling of both IL‐4/IL‐13; subcutaneous immunotherapy with Timothy grass (SCIT), which inhibits allergic responses through pleiotropic effects; SCIT + dupilumab; or placebo. Using nasal brushing samples from these studies, we defined distinct gene signatures in nasal tissue of AR disease and after nasal allergen challenge (NAC) and assessed how these signatures were modulated by study drug(s).
Results
Treatment with dupilumab (normalized enrichment score [NES] = −1.73, p = .002) or SCIT + dupilumab (NES = −2.55, p < .001), but not SCIT alone (NES = +1.16, p = .107), significantly repressed the AR disease signature. Dupilumab (NES = −2.55, p < .001), SCIT (NES = −2.99, p < .001), and SCIT + dupilumab (NES = −3.15, p < .001) all repressed the NAC gene signature.
Conclusion
These results demonstrate type 2 inflammation is an important contributor to the pathophysiology of AR disease and that inhibition of the type 2 pathway with dupilumab may normalize nasal tissue gene expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
- Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
- Clinical Research Division, Jonathan Corren, MD. Inc., Los Angeles, California, USA.
- Sanofi, Bridgewater, New Jersey, USA.
ORCID-Profile: Matthew F Wipperman, Kaitlyn M Gayvert, Jamie M Orengo, Sara C Hamon, Jennifer D Hamilton, Meagan P O'Brien
Förderung
- Regeneron Pharmaceuticals
- Sanofi
Zitieren
APA
Wipperman, M. F., Gayvert, K. M., Atanasio, A., Wang, C. Q., Corren, J., Covarrubias, A., Setliff, I., Chio, E., Laws, E., Wolfe, K., Harel, S., Maloney, J., Herman, G., Orengo, J. M., Lim, W. K., Hamon, S. C., Hamilton, J. D., & O'Brien, M. P. (2024). Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy. Allergy, 79(4), 894-907. https://doi.org/10.1111/all.16001
Vancouver
Wipperman MF, Gayvert KM, Atanasio A, Wang CQ, Corren J, Covarrubias A, et al. Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy. Allergy. 2024;79(4):894-907. doi:10.1111/all.16001
BibTeX
@article{Wipperman2024,
author = {Wipperman, Matthew F and Gayvert, Kaitlyn M and Atanasio, Amanda and Wang, Claire Q and Corren, Jonathan and Covarrubias, Angelica and Setliff, Ian and Chio, Erica and Laws, Elizabeth and Wolfe, Kelley and Harel, Sivan and Maloney, Jennifer and Herman, Gary and Orengo, Jamie M and Lim, Wei Keat and Hamon, Sara C and Hamilton, Jennifer D and O'Brien, Meagan P},
title = {Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy},
journal = {Allergy},
year = {2024},
volume = {79},
number = {4},
pages = {894--907},
doi = {10.1111/all.16001}
}
EUVIMED